Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG).
Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG).
复制标题
DOI：
10.1186/s12933-017-0622-7
复制
发表时间：
2017-10-23
影响因子：
9.3
通讯作者：
Tankova T
中科院分区：
文献类型：
--
作者：
Schernthaner G;Lehmann R;Prázný M;Czupryniak L;Ducena K;Fasching P;Janež A;Karasik A;Kempler P;Martinka E;Shestakova MV;Duvnjak LS;Tankova T
这些建议旨在改善中欧和东欧心血管（CV）高风险2型糖尿病（T2D）患者的护理。心血管疾病（CVD）和/或慢性肾脏疾病（CKD）是T2D患者的主要相互依赖的合并症，占死亡率的50%。根据最近的CV结局试验（CVOT）结果，包括EMPA-REG OUTCOME®、LEADER®、SUSTAIN ™-6和最近的CANVAS研究的结果，必须制定区域专家共识建议，以帮助医生将这些最新数据解释为临床实践。中欧和东欧糖尿病专家组（CEEDEG）遵循德尔菲方法开发治疗算法，以帮助医生对CV高风险T2D患者进行临床管理。根据最新的CVOT结果，特别是EMPA-REG OUTCOME®和LEADER®试验，T2D和确诊CVD和/或CKD患者的诊断、评估、治疗选择和监测与现有指南一起考虑，并在两种参考算法中列出。此外，遵守，特殊处方的考虑和建议的多学科管理方法进行了讨论，并提出了拟议的算法。关于降糖药物的最新可用高水平证据使CEEDG能够为确诊的CVD和/或CKD患者制定实用的共识建议。这些建议代表了对用于这些患者的国际和国家级指南的更新，目的是不仅为内分泌学家，而且为该地区的心脏病学家，肾病学家和初级保健医生提供资源。本文的在线版本（doi：10.1186/s12933 - 017 - 0622 - 7）包含补充材料，可供授权用户使用。
These recommendations aim to improve care for patients with type 2 diabetes (T2D) at high cardiovascular (CV) risk in Central and Eastern Europe. Cardiovascular disease (CVD) and/or chronic kidney disease (CKD) are major interdependent comorbidities in patients with T2D, accounting for 50% of mortality. Following recent CV outcomes trial (CVOT) results, including those from EMPA-REG OUTCOME®, LEADER®, SUSTAIN™-6 and, most recently, the CANVAS study, it is essential to develop regional expert consensus recommendations to aid physicians in interpreting these newest data to clinical practice. The Central and Eastern European Diabetes Expert Group (CEEDEG) followed a Delphi method to develop treatment algorithms to aid physicians in the clinical management of patients with T2D at high CV risk. In light of the latest CVOT results, and in particular the EMPA-REG OUTCOME® and LEADER® trials, the diagnosis, assessment, treatment choice and monitoring of patients with T2D and established CVD and/or CKD have been considered together with existing guidelines and presented in two reference algorithms. In addition, adherence, special prescribing considerations and a proposed multidisciplinary management approach have been discussed and are presented with the proposed algorithms. The latest available high-level evidence on glucose-lowering drugs has enabled CEEDEG to develop practical consensus recommendations for patients with established CVD and/or CKD. These recommendations represent an update to international and country-level guidelines used for these patients, with the aim of providing a resource not only to endocrinologists, but to cardiologists, nephrologists and primary care physicians in the region. The online version of this article (doi:10.1186/s12933-017-0622-7) contains supplementary material, which is available to authorized users.
登录
查看更多内容
影响因子：
9.3
作者：
Mohammedi K;Potier L;Belhatem N;Matallah N;Hadjadj S;Roussel R;Marre M;Velho G
通讯作者：
Velho G
影响因子：
120.7
作者：
Margulies, Kenneth B.;Hernandez, Adrian F.;Redfield, Margaret M.;Givertz, Michael M.;Oliveira, Guilherme H.;Cole, Robert;Mann, Douglas L.;Whellan, David J.;Kiernan, Michael S.;Felker, G. Michael;McNulty, Steven E.;Anstrom, Kevin J.;Shah, Monica R.;Braunwald, Eugene;Cappola, Thomas P.
通讯作者：
Cappola, Thomas P.
DOI：
10.1056/nejmoa1603827
发表时间：
2016-07-28
期刊：
The New England journal of medicine
影响因子：
--
作者：
Marso SP;Daniels GH;Brown-Frandsen K;Kristensen P;Mann JF;Nauck MA;Nissen SE;Pocock S;Poulter NR;Ravn LS;Steinberg WM;Stockner M;Zinman B;Bergenstal RM;Buse JB;LEADER Steering Committee;LEADER Trial Investigators
通讯作者：
LEADER Trial Investigators
影响因子：
6.1
作者：
Chen Xin;Yang Li;Zhai Suo-di
通讯作者：
Zhai Suo-di
影响因子：
3.3
作者：
Kaku, Kohei;Lee, Jisoo;Malano, J.
通讯作者：
Malano, J.